SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback